Journal article
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
S Peters, AT Shaw, B Besse, E Felip, BJ Solomon, RA Soo, A Bearz, SM Gadgeel, CC Lin, S Kao, T Seto, ET Masters, A Abbattista, JS Clancy, H Thurm, A Reisman, G Peltz, D Ross Camidge
Lung Cancer | ELSEVIER IRELAND LTD | Published : 2020
Abstract
Objectives: To evaluate patient-reported outcomes (PROs) from a phase 1/2 study (NCT01970865) in patients with anaplastic lymphoma kinase (ALK)- or ROS1-positive advanced non-small cell lung cancer (NSCLC) treated with lorlatinib 100 mg once daily. Materials and methods: PRO measures, including global quality of life (QoL), functioning domains and symptoms, were assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and the 13-item Lung Cancer (QLQ-LC13) module. Mean changes of absolute scores from baseline were assessed. Percentages of patients showing improvement, stability or worsening on each scale were reported,..
View full abstractGrants
Funding Acknowledgements
This study was sponsored by Pfizer Inc. Editorial support was provided by Keith Evans and Kate Williams of in Science Communications, Springer Healthcare (Chester, UK), with funding from Pfizer Inc.